H. Lundbeck A/S (HLBBF)
OTCMKTS · Delayed Price · Currency is USD
6.85
-0.45 (-6.16%)
At close: Oct 31, 2025
H. Lundbeck Revenue
H. Lundbeck had revenue of 6.02B DKK in the quarter ending June 30, 2025, with 10.45% growth. This brings the company's revenue in the last twelve months to 23.52B, up 13.79% year-over-year. In the year 2024, H. Lundbeck had annual revenue of 22.00B with 10.51% growth.
Revenue (ttm)
23.52B DKK
Revenue Growth
+13.79%
P/S Ratio
1.81
Revenue / Employee
4.12M DKK
Employees
5,707
Market Cap
6.69B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.00B | 2.09B | 10.51% |
| Dec 31, 2023 | 19.91B | 1.67B | 9.13% |
| Dec 31, 2022 | 18.25B | 1.95B | 11.95% |
| Dec 31, 2021 | 16.30B | -1.37B | -7.77% |
| Dec 31, 2020 | 17.67B | 636.00M | 3.73% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 221.55M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 2.61M |
H. Lundbeck News
- 10 days ago - Lundbeck Announces Adoption Of ChatGPT Enterprise; To Integrate AI Into Daily Workflows - Nasdaq
- 2 months ago - Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine - Benzinga
- 4 months ago - New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine - Benzinga
- 4 months ago - New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine - Benzinga
- 6 months ago - Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers - Seeking Alpha
- 8 months ago - Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan - PRNewsWire
- 10 months ago - Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade) - Seeking Alpha
- 1 year ago - Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal - Seeking Alpha